Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Neurocognitive function in HIV infected patients on antiretroviral therapy.

Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI; PIVOT Trial Team..

PLoS One. 2013 Apr 30;8(4):e61949. doi: 10.1371/journal.pone.0061949. Print 2013.

2.

Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.

Garvey L, Surendrakumar V, Winston A.

HIV Clin Trials. 2011 Nov-Dec;12(6):333-8. doi: 10.1310/hct1206-333.

PMID:
22189152
3.

Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.

Tozzi V, Balestra P, Salvatori MF, Vlassi C, Liuzzi G, Giancola ML, Giulianelli M, Narciso P, Antinori A.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. Erratum in: J Acquir Immune Defic Syndr. 2009 Dec 1;52(4):529.

PMID:
19731418
4.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
5.

Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals.

Smith PR, Sarner L, Murphy M, James B, Thomas JM, Skinner CJ, Aitken C.

J Clin Virol. 2003 Jan;26(1):101-7.

PMID:
12589840
6.

African ethnicity can influence immunological responses to highly active antiretroviral therapy and immunological success at 48 months: a retrospective pilot study.

Guillaume C, N'Guyen Y, Brodard V, Bani-Sadr F, Jaussaud R, Andreoletti L.

Int J Infect Dis. 2013 Dec;17(12):e1259-62. doi: 10.1016/j.ijid.2013.08.001. Epub 2013 Sep 12.

7.

Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy.

Cervero M, Agud JL, Torres R, García-Lacalle C, Alcázar V, Jusdado JJ, Moreno S.

HIV Med. 2013 Oct;14(9):556-62. doi: 10.1111/hiv.12049. Epub 2013 Jun 5.

8.

HIV associated neurocognitive disorders (HAND) in Malawian adults and effect on adherence to combination anti-retroviral therapy: a cross sectional study.

Kelly CM, van Oosterhout JJ, Ngwalo C, Stewart RC, Benjamin L, Robertson KR, Khoo S, Allain TJ, Solomon T.

PLoS One. 2014 Jun 10;9(6):e98962. doi: 10.1371/journal.pone.0098962. eCollection 2014.

9.

Neurocognitive Function and Neuroimaging Markers in Virologically Suppressed HIV-positive Patients Randomized to Ritonavir-boosted Protease Inhibitor Monotherapy or Standard Combination ART: A Cross-sectional Substudy From the PIVOT Trial.

Arenas-Pinto A, Stöhr W, Jäger HR, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI; PIVOT Neurocognitive sub-study Team..

Clin Infect Dis. 2016 Jul 15;63(2):257-64. doi: 10.1093/cid/ciw279. Epub 2016 May 3.

PMID:
27143662
10.

Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.

Wright EJ, Grund B, Robertson K, Brew BJ, Roediger M, Bain MP, Drummond F, Vjecha MJ, Hoy J, Miller C, Penalva de Oliveira AC, Pumpradit W, Shlay JC, El-Sadr W, Price RW; INSIGHT SMART Study Group..

Neurology. 2010 Sep 7;75(10):864-73. doi: 10.1212/WNL.0b013e3181f11bd8. Epub 2010 Aug 11.

11.

Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without nucleoside analogues.

Clarke A, Johanssen V, Gerstoft J, Clotet B, Ripamonti D, Murungi A, Bicer C, Hadacek MB, Moecklinghoff C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19526. doi: 10.7448/IAS.17.4.19526. eCollection 2014.

12.

Neurocognitive function in HIV-infected patients with low weight and weight loss.

Dolan S, Montagno A, Wilkie S, Aliabadi N, Sullivan M, Zahka N, Sherman JC, Grinspoon S.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):155-64.

PMID:
14526204
13.

Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.

Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R.

AIDS. 2011 Jan 28;25(3):357-65. doi: 10.1097/QAD.0b013e32834171f8.

14.

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Wright EJ, Grund B, Cysique LA, Robertson KR, Brew BJ, Collins G, Shlay JC, Winston A, Read TR, Price RW; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group..

HIV Med. 2015 Apr;16 Suppl 1:97-108. doi: 10.1111/hiv.12238.

15.

Central nervous system antiretroviral penetration and cognitive functioning in largely pretreated HIV-infected patients.

Casado JL, Marín A, Moreno A, Iglesias V, Perez-Elías MJ, Moreno S, Corral I.

J Neurovirol. 2014 Feb;20(1):54-61. doi: 10.1007/s13365-013-0228-0. Epub 2014 Jan 14.

PMID:
24420449
16.

Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.

Winston A, Puls R, Kerr SJ, Duncombe C, Li PC, Gill JM, Taylor-Robinson SD, Emery S, Cooper DA; Altair Study Group..

HIV Med. 2012 Apr;13(4):245-51. doi: 10.1111/j.1468-1293.2011.00962.x. Epub 2011 Dec 12.

17.

Neurocognitive functioning in pediatric human immunodeficiency virus infection: effects of combined therapy.

Shanbhag MC, Rutstein RM, Zaoutis T, Zhao H, Chao D, Radcliffe J.

Arch Pediatr Adolesc Med. 2005 Jul;159(7):651-6.

PMID:
15996999
18.

Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.

Marra CM, Lockhart D, Zunt JR, Perrin M, Coombs RW, Collier AC.

Neurology. 2003 Apr 22;60(8):1388-90.

19.

Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.

Ciccarelli N, Fabbiani M, Colafigli M, Trecarichi EM, Silveri MC, Cauda R, Murri R, De Luca A, Di Giambenedetto S.

Antivir Ther. 2013;18(2):153-60. doi: 10.3851/IMP2560. Epub 2013 Mar 13.

PMID:
23486721
20.

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).

Vibhagool A, Cahn P, Schechter M, Smaill F, Soto-Ramirez L, Carosi G, Montroni M, Pharo CE, Jordan JC, Thomas NE, Pearce G.

Curr Med Res Opin. 2004 Jul;20(7):1103-14.

PMID:
15265255

Supplemental Content

Support Center